Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q2 and Q3 2022 Earnings Conference Call December 20, 2022 5:00 PM ET

Company Participants

Julie Gannon - Chief of Staff and Investor Relations

Kirk Huntsman - Chairman and Chief Executive Officer

Brad Amman - Chief Financial Officer

Conference Call Participants

Scott Henry - ROTH Capital

Alexander Nowak - Craig-Hallum Capital Group

Operator

Good day, everyone and welcome to the Vivos Therapeutics Second and Third Quarter 2022 Earnings Conference Call. At this time participants are in a listen-only mode. A question-and-answer session will follow management’s remarks. This conference call is being recorded and a replay of today’s call will be available on the Investor Relations section of Vivos’ website and will remain posted there for the next 30 days.

I will now hand the call over to Julie Gannon, Vivos’ Investor Relations Officer for introductions and the reading of the Safe Harbor statement. Please go ahead.

Julie Gannon

Thank you, operator. Hello everyone. And welcome to Vivos’ Therapeutics second and third quarter 2022 earnings conference call. A copy of our earnings press release is available on the Investor Relations section of our website at www.vivos.com.

With us on today’s call are Kirk Huntsman, Vivos’ Chairman and Chief Executive Officer; and Brad Amman, Chief Financial Officer. Today we’ll review the highlights and financial results for the second and third quarter of 2022, as well as more recent developments and Vivos' plans for 2023. Following these formal remarks, we will be prepared to answer your questions.

I would also like to remind everyone that today’s call will contain certain forward-looking statements from our management made within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities and Exchange Act of 1934 as amended, concerning future events. Words such as aim, may, could, should, project, expect, intends, plans, believes, anticipates, hopes, estimates and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon a number of assumptions and estimates which are inherently subject to significant risk, uncertainties and contingencies, many of which are beyond the company’s control.

Actual results, including without limitation the results of Vivos growth strategies, operational plans, including cost savings plans and plans to generate revenue, future potential results of operations or operating metrics, and other matters to be addressed by Vivos management in this conference call, may differ materially and adversely from those expressed or implied by such forward-looking statements.